NexGel Q3 EPS $(2.28) Beats $(4.80) Estimate, Sales $3.179M Miss $4.190M Estimate
NEXGEL Announces Noteholder Participation in Strategic Recapitalization and Approximately $1.2 Million in New Capital Funding
NEXGEL Advances Recapitalization As Noteholders Agree To Convert $14.1M Of Debt
NEXGEL Regains Compliance with Nasdaq Listing Requirement
NEXGEL Regains Nasdaq Compliance
NEXGEL Announces 1-for-20 Reverse Stock Split Effectiveness
NEXGEL Announces 1-For-20 Reverse Stock Split, Effective Immediately
NEXGEL, Inc. (NXGL) Discusses Strategic Platform Reorganization and Refocus on Medical Device and Biomedical Innovation Transcript
NEXGEL Announces Dial-In Details for Investor Update Call
NEXGEL Announces Date for Investor Update Call
Maxim Group Downgrades NexGel to Hold
NEXGEL ANNOUNCES LEADERSHIP TRANSITION AND STRATEGIC REVIEW INITIATIVE
NEXGEL Appoints Brian Kieser As Interim CEO; Co. Forms Special Committee For Strategic Review And Value Creation
NEXGEL Q2 Revenue Reaches $3.69 Million as BioNX Integration Faces Slower Ramp
NEXGEL Reports Second Quarter 2026 Financial Results
NexGel Q2 EPS $(0.40) Misses $(0.12) Estimate, Sales $3.686M Miss $4.315M Estimate
NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th –18th
NEXGEL Reports Positive Data from Randomized Single-Center IRB Study to Evaluate the Effectiveness and Safety of a Hydrogel Laser Treatment Patch in Laser Hair Removal with a 95.6% Reduction in Plume Concentration
NEXGEL Announces Data From Randomized, 30-Patient, Single-Center IRB Clinical Study, Funded By Innovative Optics
Nexgel (NXGL) Q1 2026 Earnings Transcript
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.